

ACTA MEDICINAE 1/2013 BIOLOGICKÁ LÉČBA

Kompletní literatura

- 2 **Inhibice interleukinů 12 a 23 – zkušenosti s léčbou ložiskové lupénky ustekinumabem**
doc. MUDr. Karel Ettler, CSc. | MUDr. Jiří Ettler Klinika nemocí kožních a pohlavních FN a LF UK, Hradec Králové
- 3 **Léčba infliximabem v dermatologii**
PharmDr. Lenka Součková Ph.D. Anesteziologicko-resuscitační klinika,
Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně
- 3 **Biologická léčba revmatických onemocnění**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav Praha
- 5 **Biologická léčba ankylozující spondylitidy adalimumabem**
MUDr. Pavel Jeremiáš Oddělení klinické farmakologie FN Plzeň
- 5 **Využití golimumabu v léčbě aktivní revmatoidní artritidy**
MUDr. David Suchý, PhD. Oddělení klinické farmakologie FN Plzeň
- 5 **Biologická léčba v terapii revmatoidní artritidy**
MUDr. Hana Brabcová Oddělení klinické farmakologie, Fakultní nemocnice Plzeň
- 5 **Dlouhodobá léčba roztroušené sklerózy mozkomíšní a lékový switch**
doc. MUDr. Radomír Taláb, CSc. LF UK v Hradci Králové
- 6 **Léčba intramuskulárním interferonem beta-1a**
MUDr. Eva Krasulová Centrum pro demyelinizační onemocnění, Neurologická klinika
a Centrum klinických neurověd, 1. LF UK a VFN v Praze
- 6 **Doporučení pro léčbu metastatického renálního karcinomu**
doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 6 **Pazopanib**
MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha
- 7 **Současné možnosti biologické léčby karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha
- 7 **Biologická léčba chronické virové hepatitidy B a C**
doc. MUDr. Petr Urbánek, CSc. Interní klinika 1. LF UK a ÚVN Praha
- 8 **Crohnova nemoc a ulcerózní kolitida: klinický obraz, diagnostika a biologická léčba**
prof. MUDr. Milan Lukáš, CSc. Klinické a výzkumné centrum pro střevní záněty ISCARE I.V.F., a. s.,
a Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK, Praha
- 8 **Očkování v prevenci rakoviny děložního hrdla**
MUDr. Lucie Mouková Masarykův onkologický ústav Brno, Oddělení gynekologické onkologie

Inhibice interleukinů 12 a 23 – zkušenosti s léčbou ložiskové lupénky ustekinumabem

doc. MUDr. Karel Ettler, CSc. | MUDr. Jiří Ettler

Klinika nemocí kožních a pohlavních FN a LF UK, Hradec Králové

- 1 **Kimball, A. B. – Jacobson, C. – Weiss, S., et al.:** The psychosocial burden of psoriasis. *Am J Clin Dermatol*, 2005, 6, s. 383–392.
- 2 **Henseler, T. – Christophers, E.:** Disease concomitance in psoriasis. *J Am Acad Dermatol*, 1995, 32, s. 982–986.
- 3 **Griffiths, C. E. M. – Girolomoni, G.:** Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis? *JEADV*, 2012, 26, s. 2–8.
- 4 **Oppmann, B. – Lesley, R. – Blom, B., et al.:** Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. *Immunity*, 2000, 13, s. 715–725.
- 5 **Lee, E. – Trepicchio, W. L. – Oestreicher, J. L., et al.:** Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. *J Exp Med*, 2004, 199, s. 125–130.
- 6 **Wilson, N. J. – Boniface, K. – Chan, J. R., et al.:** Development, cytokine profile and function of human interleukin 17-producing helper T cells. *Nat Immunol*, 2007, 8, s. 950–957.
- 7 **Benáková, N.:** Ustekinumab v celkové léčbě psoriázy. *Farmakoterapie*, 2009, 5, s. 249–356.
- 8 **Lebwohl, M. – Yeilding, N. – Szapary, P., et al.:** Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. *J Am Acad Dermatol*, 2010, 63, s. 571–579.
- 9 **Leopardi, C. L. – Kimball, A. B. – Papp, K. A., et al.:** Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). *Lancet*, 2008, 371, s. 1665–1674.
- 10 **Papp, K. A. – Lebwohl, M. – Krueger, G. G., et al.:** Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). *Lancet*, 2008, 371, s. 1675–1684.
- 11 **Griffiths, C. E. M. – Strober, B. E. – van de Kerkhof, P., et al.:** Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. *N Engl J Med*, 2010, 362, s. 118–128.
- 12 **Reich, K. – Nestle, F. O. – Papp, K., et al.:** Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. *Lancet*, 2005, 366, s. 1367–1374.
- 13 **Wallis, R. S. – Broder, M. – Wong, J., et al.:** Reactivation of latent granulomatous infections by infliximab. *Clin Infect Dis*, 2005, 41, s. 194–198.
- 14 **Beadling, C. – Slifka, M. K.:** Regulation of innate and adaptive immune responses by the related cytokines IL-12, IL-23, and IL-27. *Arch Immunol Ther Exp (Warsz)*, 2006, 54, s. 15–24.
- 15 **Khader, S. A. – Partida-Sanchez, S. – Bell, G., et al.:** Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. *J Exp Med*, 2006, 203, s. 1805–1815.
- 16 **Langowski, J. L. – Zhang, X. – Wu, L., et al.:** IL-23 promotes tumour incidence and growth. *Nature*, 2006, 442, s. 461–465.
- 17 **Fieschi, C. – Casanova, J.:** The role of interleukin-12 in human infectious diseases: only a faint signature. *Eur J Immunol*, 2003, 33, s. 1461–1464.
- 18 **Gordon, K. B. – Papp, K. A. – Langley, R. G., et al.:** Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. *J Am Acad Dermatol*, 2012, 66, s. 742–751.
- 19 **Brown, S. L. – Greene, M. H. – Gershon, S. K., et al.:** Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. *Arthritis Rheum*, 2002, 46, s. 3151–3158.
- 20 **Bongartz, T. – Sutton, A. J. – Sweeting, M. J., et al.:** Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA*, 2006, 295, s. 2275–2285.
- 21 **Mariette, X. – Tubach, F. – Bagheri, H., et al.:** Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. *Ann Rheum Dis*, 2010, 69, s. 400–408.
- 22 **Papp, K. – Ho, V. – Yeilding, N., et al.:** Malignancies in Ustekinumab-treated moderate-to-severe Psoriasis patients: observations with up to 3 years of follow-up and comparisons to the general United States population. Poster prezentovaný na 19. kongresu EADV, 6.–10. 10. 2010, Göteborg. Poster P554.
- 23 **Reich, K. – Langley, R. G. – Lebwohl, M., et al.:** Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. *Br J Dermatol*, 2011, 164, s. 862–872.
- 24 **Clemmensen, A. – Spon, M. – Skov, L., et al.:** Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. *J Eur Acad Dermatol Venereol*, 2011, 25, s. 1037–1040.
- 25 **Ettler, J. – Ettler, K.:** Hodnocení biologické léčby psoriázy – zkušenosti jednoho centra 2006–2011. Poster prezentovaný na Rezidence patří dermatologii, 8. 11. 2012, Praha.
- 26 <http://www.clinicaltrials.gov/ct2/show/NCT01090427?term=CADMUS&rank=1>, vyhledáno 31. 1. 2013.
- 27 **Kimball, A. B. – Papp, K. A. – Wasfi, Y., et al.:** Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. *JEADV*, 20. 12. 2012, doi: 10.1111/jdv.12046.
- 28 **Tsai, T. F. – Ho, V. – Song, M., et al.:** The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. *BJD*, 29. 10. 2012, doi: 10.1111/j.1365-2133.2012.11142.x.
- 29 **European Medicines Agency, Press Release, EMA/40297/2011, www.ema.europa.eu.**

Léčba infliximabem v dermatologii

PharmDr. Lenka Součková Ph.D. Anesteziologicko-resuscitační klinika,
Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně

- 1 Mrowietz, U. – Reich, K.: Ten years of infliximab: Its role in dermatology. *Eur J Pharmacol*, 2009, 623, s. 10–16.
- 2 Partsch, G. – Steiner, G. – Leeb, B. F., et al.: Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. *J Rheumatol*, 1997, 24, s. 518–523.
- 3 SPC Remicade.
- 4 Bongartz, T. – Sutton, A. J. – Sweeting, M. J., et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA*, 2006, 11, s. 1–4.
- 5 Calabrese, L. H.: Molecular differences in anticytokine therapies. *Clin Exp Rheumatol*, 2003, 21, s. 241–248.
- 6 Furst, D. E. – Wallis, R. – Broder, M. – Beenhouwer, D. O.: Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. *Semin Arthritis Rheum*, 2006, 36, s. 159–167.
- 7 Scallon, B. – Cai, A. – Solowski, N., et al.: Binding and functional comparisons of two types of tumor necrosis factor antagonists. *J Pharmacol Exp Ther*, 2002, 301, s. 418–426.
- 8 Michael, A. – Gardam, E. C. – Keystone, R. – Menzies, R. – Manners, S. – Skamene, E. – Long, R. – Vinh, D. C.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. *The Lancet Infectious Diseases*, 2003, 3, s. 148–155.
- 9 Menter, A. – Griffiths, C. E.: Current and future management of psoriasis. *Lancet*, 2007, 370, s. 272–284.
- 10 Gottlieb, A. B. – Evans, R. – Li, S., et al.: Infliximab induction therapy for patients with severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. *J Am Acad Dermatol*, 2004, 51, s. 534–542.
- 11 Feldman, S. R. – Gordon, K. B. – Bala, M., et al.: Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. *Br J Dermatol*, 2005, 152, s. 954–960.
- 12 Khana, D. – McMahon, M. – Furst, D. E.: Safety of tumour necrosis factor—alpha antagonists. *Drug Saf*, 2004, 27, s. 307–324.
- 13 Jacobi, A. – Antoni, C. – Manger, B. – Schuler, G. – Hertl, M.: Infliximab in the treatment of moderate to severe atopic dermatitis. *J Am Acad Dermatol*, 2005, 52, s. 522–526.
- 14 Sené, T., et al.: Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: Single-center retrospective study of 9 patients. *J Am Acad Dermatol*, 2012, 66, s. 328–32.
- 15 Brooklyn, T. N. – Dunnill, M. G. S. – Shetty, A. – Bowden, J. J. – Williams, J. D. L. – Griffiths, C. E. M. – Forbes, A. – Greenwood, R. – Probert, C. S.: Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. *Gut*, 2006, 55, s. 505–509.
- 16 Bos, J. D. – Mekkes, J. R.: Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. *British J Dermatol*, 2008, 158, s. 370–374.

Biologická léčba revmatických onemocnění

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav Praha

- 1 Pincus, T. – Callahan, L. F. – Sale, W. G., et al.: Severe functional declines, work disability and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis Rheum*, 1984, 27, s. 864–872.
- 2 Visser, K. – van der Heide, D.: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. *Ann Rheum Dis*, 2009, 68, s. 1094–1099.
- 3 van Vollenhoven, R. F. – Fleischmann, R. – Cohen, S., et al.: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 508–519.
- 4 Cush, J. – Kavanaugh, A.: TNF alfa blocking therapies. In: *Rheumatology*, Ed. Hochberg, M. – Silman, A. J. – Smolen, J., et al.: 4. vydání. Londýn, Mosbz, 2008, s. 501–519.
- 5 Pavelka, K. – Jarosova, K. – Suchý, D., et al.: Increasing the infliximab dose in rheumatoid arthritis patients: A randomised, double blind study failed to confirm its efficacy. *Ann Rheum Dis*, 2009, 68, s. 1285–1289.
- 6 Maini, R. N. – Breedveld, F. C. – Kalden, J. R., et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alfa monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum*, 1998, 41, s. 1552–1563.
- 7 St Clair, E. W. – van der Heide, D. M. – Smolen, J. S., et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. *Arthritis Rheum*, 2004, 50, s. 3432–3443.
- 8 Goekoop-Ruiterman, Y. P. – Vries Boustra, J. K., et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early RA (the BEST study): A randomized controlled trial. *Arthritis Rheum*, 2005, 52, s. 3381–3390.
- 9 Braun, J. – Barraliakos, X. – Listing, J., et al.: Persistent clinical efficacy and safety of anti-TNF therapy with infliximab in patients with AS over 5 years: evidence for different types of response. *Ann Rheum Dis*, 2008, 67, s. 340–345.
- 10 Barkham, N. – Keen, H. I. – Coates, L. C., et al.: Clinical and imaging efficacy of infliximab in HLA B27 positive patients with MRI determined early sacroiliitis. *Arthritis Rheum*, 2006, 60, s. 946–94.
- 11 Kavanaugh, A. – Tutuncu, Z. – Cattalan Sanchez, T.: Update on anti-TNF factor therapy in the spondylarthropathies including psoriatic arthritis. *Curr Opin Rheumatol*, 2006, 18, s. 347–353.
- 12 Klareskog, L. – van der Heide, D. M. – de Jager, J. P., et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double blind randomised controlled trial. *Lancet*, 2004, 363, s. 675–681.
- 13 Emery, P. – Breedveld, F. C. – Hall, S., et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double blind, parallel treatment trial. *Lancet*, 2008, 372, s. 372–382.
- 14 Davis, J. C. – van der Heide, D. M. – Barun, J.: Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. *Ann Rheum Dis*, 2008, 67, s. 346–352.
- 15 Braun, J. – van der Horst-Bruinsma, I. E. – Huang, F., et al.: Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: A randomized, double blind trial. *Arthritis Rheum*, 2011, 63, s. 1543–1551.
- 16 Song, I. H. – Hermann, K. G. – Haibel, H., et al.: Effects of etanercept versus sulfasalazine in early axial spondylarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): A 48 week randomised controlled trial. *Ann Rheum Dis*, 2011, 70, s. 590–596.

- 17 Mease, P. J. – Wooley, J. M. – Singh, A., et al.: Patient reported outcomes in a randomised trial of etanercept in psoriatic arthritis. *J Rheumatol*, 2010, 37, s. 1221–1227.
- 18 Breedveld, F. – Weisman, M. H. – Kavanaugh, A., et al.: The PREMIER study: A multicenter, randomized, double blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not previous methotrexate treatment. *Arthritis Rheum*, 2006, 54, s. 26–37.
- 19 van der Heide, D. – Kivitz, A. – Schiff, H. M., et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2006, 54, s. 2136–2146.
- 20 Haibel, H. – Rudwaleit, M. – Listing, J., et al.: Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis Rheum*, 2008, 58, s. 1981–1991.
- 21 Mease, P. J. – Ory, P. – Sharp, J. T., et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2 year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). *Ann Rheum Dis*, 2009, 68, s. 702–709.
- 22 Keystone, E. – van der Heide, D. – Mason, D., et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Findings of a fifty-two-week, phase III, multicenter, randomized, double blind, placebo controlled study, parallel group study. *Arthritis Rheum*, 2008, 58, s. 3319–3329.
- 23 Fleischmann, R. – Vencovský, J. – Vollenhoven, R. F., et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease modifying antirheumatic therapy: The FAST4WARD study. *Ann Rheum Dis*, 2009, 68, s. 805–811.
- 24 Weinblatt, M. E. – Fleischmann, R. – Huizenga, T. W., et al.: Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the REALISTIC phase IIIb study. *Rheumatology (Oxford)*, 2012, 51, s. 2204–2214.
- 25 Conaghan, P. G. – Emery, P. – Ostergaard, M., et al.: Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: Results of the GO-FORWARD trial. *Ann Rheum Dis*, 2011, 70, s. 1968–1974.
- 26 Smolen, J. S. – Kay, J. – Doyle, M. K., et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors (GO-AFTER study) a multicentre, randomised, double blind, placebo controlled phase III study. *Lancet*, 2009, 374, s. 210–221.
- 27 Emery, P. – Fleischmann, R. M. – Moreland, L. W., et al.: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate naive patients with active rheumatoid arthritis: Twenty four week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first/line therapy for early-onset RA. *Arthritis Rheum*, 2009, 60, s. 2272–2283.
- 28 Braun, J. – Baraliakos, X. – Hermann, K. G., et al.: Golimumab reduces spinal inflammation in ankylosing spondylitis. MRI results of the randomised, placebo-controlled GO-RAISE study. *Ann Rheum Dis*, 2012, 71, s. 878–884.
- 29 Kavanaugh, A. – Mease, P.: Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: Longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL). *J Rheumatol*, 2012, 89 (dopl.), s. 90–93.
- 30 Dixon, W. G. – Hyrich, K. L. – Watson, K. D., et al.: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). *Ann Rheum Dis*, 2010, 69, s. 522–528.
- 31 Vencovský, J.: Bezpečnost biologické léčby – doporučení České reumatologické společnosti. *Čes Revmatol*, 2009, 17, s. 146–160.
- 32 Singh, J. A. – Christensen, R. – Weels, G. A., et al.: Biologics for rheumatoid arthritis: An overview of Cochrane reviews. *Cochrane Database Syst Rev*, 2009, 4, CD007848.
- 33 Emery, P. – Fleischmann, R. – Filipowicz-Sosnowska, A., et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheumatism*, 2006, 54, s. 1390–1400.
- 34 Cohen, S. B. – Emery, P. – Greenwald, M. W., et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis therapy: Results of a multicenter, randomized, double, blind, placebo controlled, phase III trial evaluating primary efficacy and safety at twenty four weeks. *Arthritis Rheum*, 2006, 54, s. 2793–2806.
- 35 Tak, P. P. – Rigby, W. F. – Rubbert-Roth, A., et al.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active RA. The IMAGE trial. *Ann Rheum Dis*, 2011, 70, s. 39–46.
- 36 Van Vollenhoven, R. F. – Chatzidionisou, T. – Gabay, C., et al.: Rheumatoid factor predicts response to rituximab in European registry-based cohort: 6 months results from CERRERRA. *Ann Rheum Dis*, 2009, 68, s. 579.
- 37 Buch, M. – Smolen, J. S. – Betteredge, N., et al.: Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. *Ann Rheum Dis*, 2011, 70, s. 909–920.
- 38 Jones, G. – Sebba, A. – Gu, J., et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis. The AMBITION study. *Ann Rheum Dis*, 2010, 69, s. 88–96.
- 39 Smolen, J. S. – Baeuliean, A. – Rubbert-Roth, A., et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patient with RA (OPTION study): A double blind, placebo-controlled, randomised trial. *Lancet*, 2008, 371, s. 987–997.
- 40 Genovese, M. C. – McKay, J. D. – Nasonov, J., et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity with inadequate response to disease-modifying antirheumatic drugs. *Arthritis Rheum*, 2008, 10, s. 2968–2980.
- 41 Emery, P. – Keystone, E. – Tony, H. P., et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti tumor necrosis biologicals, results from a 24 week, multicentre, randomised, placebo controlled trial. *Ann Rheum Dis*, 2008, 67, s. 1516–1523.
- 42 Kremer, J. L. – Blanco, R. – Brzosko, M., et al.: Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis Rheum*, 2011, 63, s. 609–621.
- 43 Gabay, C. – Emery, P. – Vollenhoven, R., et al.: Tocilizumab monotherapy is superior to adalimumab monotherapy in reducing disease activity in patients with RA: 24 week data from the phase IV ADACTA trial. *Ann Rheum Dis*, 2012, abstrakt, s. 152.
- 44 Koike, T. – Hariagi, M. – Ishiguro, S., et al.: Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients. *Ann Rheum Dis*, 2011, 70, s. 2148–2151.
- 45 Smolen, J. – Schoels, M. – Nishimoto, N., et al.: Consensus statement on blocking the effects of interleukin-6 receptor and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. *Ann Rheum Dis*, 2012, s. 21 (publikováno před tiskem).
- 46 Kremer, J. M., et al.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial. *Ann Intern Med*, 2006, 144, s. 865–876.
- 47 Schiff, M. – Keiserman, M. – Codding, Ch., et al.: Clinical response and

- tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: Open-label extension of the ATTEST Study. *Ann Rheum Dis*, 2011, 70, s. 2003–2007.
- 48 **Genovese, M. C., et al.**: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med*, 2005, 353, s. 1114–1123.
- 49 **Pavelka, K. – Vencovský, J.**: Doporučení České reumatologické společnosti pro léčbu revmatoidní artritidy. *Česká Revmatologie*, 2010, 4, s. 182–191.
- 50 **Pavelka, K.**: Doporučení České reumatologické společnosti pro léčbu ankylozující spondylitidy. *Česká revmatologie*, 2012, 1, s. 4–12.
- 51 **Štolfa, J. – Vencovský, J. – Pavelka, K.**: Doporučení České reumatologické společnosti pro léčbu psoriatické artritidy. *Česká Revmatologie*, 2012, 1, s. 13–18.
- 52 **Weir, N. – Athwal, D., et al.**: Therapy. *Future medicine*, 2006, 3, s. 535–545.

Biologická léčba ankylozující spondylitidy adalimumabem

MUDr. Pavel Jeremiáš Oddělení klinické farmakologie FN Plzeň

- Braun, J. – Bollow, M. – Remlinger, G., et al.**: Prevalence of spondylarthropathies in HLA B27 positive and negative blood donors. *Arthritis Rheum*, 1998, 41, s. 58–67.
- Rudwaleit, M. – Metter, A. – Listing, J., et al.**: Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. *Arthritis Rheum*, 2006, 54, s. 569–578.
- van der Linden, S. – Valkenburg, H. A. – Cats, A.**: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum*, 1984, 27, s. 361–368.
- Rudwaleit, M. – van der Heide, D. – Landewe, R.**: Development of ASAS for axial spondylarthritis, validation of final section. *Ann Rheum Dis*, 2009, 68, s. 777–783.
- van der Heijde, D. – Revicki, D. A. – Gooch, K. L., et al.**: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. *Arthritis Res Ther*, 2009, 11, s. 124.
- van der Heijde, D. – Kivitz, A. – Schiff, M. H., et al.**: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2006, 54, s. 2136–2146.
- Rudwaleit, M. – Claudepierre, P. – Wordsworth, P., et al.**: Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. *J Rheumatol*, 2009, 36, s. 801–808.
- Botteman, M. F. – Hay, J. W. – Luo, M. P., et al.**: Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. *Rheumatology (Oxford)*, 2007, 46, s. 1320–1328.

Využití golimumabu v léčbě aktivní revmatoidní artritidy

MUDr. David Suchý, PhD. Oddělení klinické farmakologie FN Plzeň

- Kay, J. – Rahman, M. U.**: Golimumab: A novel human anti-TNF α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. *Core Evidence*, 2009, 4, s. 159–170.
- Šenolt, L.**: Golimumab. *Remedia*, 2010, 20, s. 164–171.
- Němec, P.**: Golimumab. *Farmakoterapie*, 2010, 6, s. 11–18.
- Domne, B. – Dasgupta, B. – Low, I., et al.**: Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs. *Arthritis Rheum*, 2012, 10, s. 205.
- Snesly, D. – Cai, A. – Nesspor, T., et al.**: Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNF α [abstract]. *Ann Rheumatic Dis*, 2007, 66, s. 151.

Biologická léčba v terapii revmatoidní artritidy

MUDr. Hana Brabcová Oddělení klinické farmakologie, Fakultní nemocnice Plzeň

- Slíva, J.**: Tocilizumab v léčbě revmatoidní artritidy a systémové juvenilní artritidy. *ACTA MEDICINAE*, 2012, 4, s. 16.
- Pavelka, K.**: *Farmakoterapie revmatických onemocnění*. Grada, 2005, s. 215–235.

Dlouhodobá léčba roztroušené sklerózy mozkomíšni a lékový switch

doc. MUDr. Radomír Taláb, CSc. LF UK v Hradci Králové

- Zapletalová, O.**: Léčba časných stadií roztroušené sklerózy mozkomíšni. *Remedia*, 2009, 19, s.198–204.
- Havrdová, E.**: Roztroušená skleróza. *Neurol pro praxi*, 2008, 9, s. 208.
- Sorensen, P. S. – Deisenhammer, F. – Duda, P., et al.**: Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis. *Eur J Neurol*, 2005, 12, s. 817–827.
- Bertolotto, A.**: Neutralizing antibodies to IFN- β : Implications for the management of MS. *Curr Opin Neurol*, 2004, 17, s. 241–246.
- Hesle, D. – Sorensen, P. S.**: Swing measurements of neutralizing antibodies: The challenge of IFN- β therapy. *Eur J Neurol*, 2007, 14, s. 850–859.
- Malucchi, S., et al.**: One-year evaluation of factors affecting the

- biological activity of IFN- β in MS patients. *J Neurol*, 2011, 258, s. 895–903.
- 7 **Polman, Ch. H., et al.:** Recommendations for clinical use of data on neutralising antibodies to IFN- β therapy in MS. *Lancet Neurol*, 2010, 9, s. 740–750.
- 8 **Wiendl, H. – Toyka, K. V. – Rieckmann, P. – Gold, R. – Hartung, H. P. – Hohlfeld, R. – Multiple Sclerosis Therapy Consensus Group (MSTCG):** Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. *J Neurol*, 2008, 255, s. 1449–1463.

Léčba intramuskulárním interferonem beta-1a

MUDr. Eva Krasulová Centrum pro demyelinizační onemocnění, Neurologická klinika
a Centrum klinických neurověd, 1. LF UK a VFN v Praze

- 1 **Havrdová, E.:** *Neuroimunologie*. Praha, Maxdorf, 2001, s. 180–263.
- 2 **Jacobs, L. D. – Cookfair, D. L. – Rudick, R. A., et al.:** Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Ann Neurol*, 1996, 39, s. 285–294.
- 3 **Simon, J. H., – Jacobs, L. D. – Campion, M., et al.:** Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. *Ann Neurol*, 1998, 43, s. 79–87.
- 4 **Jacobs, L. D. – Beck, R. W. – Simon, J. H., et al.:** Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. *N Engl J Med*, 2000, 343, s. 898–904.
- 5 **Kinkel, R. P. – Kollman, C. – O'Connor, P., et al.:** IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. *Neurology*, 2006, 66, s. 678–684.
- 6 **Gneiss, C. – Tripp, P. – Reichartseder, F., et al.:** Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. *Mult Scler*, 2006, 2, s. 731–737.
- 7 **Herndon, R. M. – Rudick, R. A. – Munschauer, F. E., et al.:** Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. *Mult Scler*, 2005, 11, s. 409–419.
- 8 **Devonshire, V. – Lapierre, Y. – Macdonnell, R., et al.:** The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. *Eur J Neurol*, 2011, 18, s. 69–77.

Doporučení pro léčbu metastatického renálního karcinomu

doc. MUDr. Tomáš Büchler, Ph.D. Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 **Dušek, L. – Mužík, J. – Kubásek, M., et al.:** *Epidemiologie zhoubných nádorů v České republice* [online]. Masarykova univerzita, 2005, vyhlášeno 7. 1. 2013, dostupné z www.svod.cz.
- 2 **Escudier, B. – Eisen, T. – Porta, C., et al.:** Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2012, 23, dopl. 7, vii65–71.
- 3 **Motzer, R. J. – Hutson, T. E. – Reeves, J., et al.:** Randomized, open label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC); Results of the COMPARZ trial: Presented at the 37th Congress of the European Society for Medical Oncology (ESMO). Vídeň, Rakousko, 28. 9.–2. 10. 2012, abstrakt LBA8.
- 4 **Escudier, B. – Pluzanska, A. – Koralewski, P., et al.:** AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet*, 2007, 370, s. 2103–2111.
- 5 **Hudes, G. – Carducci, M. – Tomczak, P., et al.:** Global ARCC Trial.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 2271–2281.
- 6 **Motzer, R. J. – Escudier, B. – Oudard, S., et al.:** Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. *Lancet*, 2008, 372, s. 449–456.
- 7 **Rini, B. I. – Escudier, B. – Tomczak, P., et al.:** Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. *Lancet*, 2011, 378, s. 1931–1939.
- 8 **Escudier, B. – Eisen, T. – Stadler, W. M., et al.:** Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med*, 2007, 356, s. 125–134.
- 9 **Büchler, T. – Klapka, R. – Melichar, B., et al.:** Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma — data from the Czech registry. *Ann Oncol*, 2012, 23, s. 395–401.

Pazopanib

MUDr. Jiří Slíva, Ph.D. Ústavy farmakologie 2. a 3. LF UK, Praha

- 1 **Nieto, M. – Borregaard, J. – Erbsoll, J., et al.:** The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. *Clin Cancer Res*, 2011, 17, s. 6608–6614.
- 2 **Hutson, T. E. – Davis, I. D. – Machiels, J. P., et al.:** Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2010, 28, s. 475–480.
- 3 **Sternberg, C. N. – Davis, I. D. – Mardiak, J., et al.:** Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. *J Clin Oncol*, 2010, 28, s. 1061–1068.
- 4 **van der Graaf, W. T. – Blay, J. Y. – Chawla, S. P., et al.:** Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, 2012, 379, s. 1879–1886.
- 5 **Eichbaum, M. – Mayer, C. – Eickhoff, R., et al.:** The PACOVAR-trial: A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. *BMC Cancer*, 2011, 11, s. 453.

Současné možnosti biologické léčby karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN Motol, Praha

- 1 Mok, T. – To, K. F. – Srimuninimit, V., et al.: Clinical outcomes of patients with epidermal growth factor receptor (EGFR) mutations in IPASS (Iressa Pan Asia Study) [abstract B9.5]. *J Thorac Oncol*, 2009, 4, s. 351.
- 2 Zhou, C. – Wu, Y.-L. – Chen, G., et al.: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*, 2011, 12, s. 735–742.
- 3 Zhou, C., et al.: Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2012, 30, s. 485 (abstrakt 7520).
- 4 Rosell, R., et al.: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. *Lancet Oncol*, 2012, 13, s. 239–246.
- 5 Rosell, R., et al.: Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (v3). *Ann Oncol*, 2012, 23, s. 22 (abstrakt LBA31).
- 6 Capuzzo, F., et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol*, 2010, 11, s. 521–529.
- 7 Ciuleanu, T., et al.: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): A randomised multicentre, open-label, phase 3 study. *Lancet Oncol*, 2012, 13, s. 300–308.
- 8 Johnson, D. H. – Fehrenbacher, L. – Novotny, W. F., et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. *J Clin Oncol*, 2004, 22, s. 2184–2191.
- 9 Sandler, A., et al.: Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. *NEJM*, 2006, 355, s. 2542–2550.
- 10 Reck, M. – von Pawel, J. – Zatloukal, P., et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. *J Clin Oncol*, 2009, 27, s. 1227–1234.
- 11 Crino, L., et al.: Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. *Lancet Oncol*, 2010, 11, s. 733–740.
- 12 Yang, J. Ch. H. – Schuler, M. H. – Yamamoto, N., et al.: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. *J Clin Oncol*, 2012, 30, abstrakt LBA7500.
- 13 Horn, L. – Pao, W.: EML4-ALK: honing in on a new target in non-small-cell lung cancer. *J Clin Oncol*, 2009, 27, s. 4232–4235.
- 14 Kwak, E. L. – Bang, Y. – Camidge, D. R., et al.: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med*, 2010, 363, s. 1693–1703.
- 15 Kris, M. G., et al.: *J Clin Oncol*, 2011, 29, dopl. (abstrakt 7506). Dostupné z: <http://www.etop-eu.org>.

Biologická léčba chronické virové hepatitidy B a C

doc. MUDr. Petr Urbánek, CSc. Interní klinika 1. LF UK a ÚVN Praha

- 1 Algranati, N. E. – Sy, S. – Modi, M.: A branched methoxy 40kDa polyethylen glycol (PEG) moiety optimizes the pharmacokinetics (PK) of pegIFN alfa-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). *Hepatology*, 1999, 30, s. 190.
- 2 Chen, C. J. – Yang, H. I. – Su, J., et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA*, 2006, 295, s. 65–73.
- 3 Fried, M. W.: Side effects of therapy of hepatitis C and their management. *Hepatology*, 2002, 36, s. 237–244.
- 4 Urbánek, P. – Husa, P. – Galský, J. – Šperl, J. – Hejda, V. – Kumpel, P. – Němeček, V. – Plíšek, S. – Volfová, M.: Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). *Gastroenterologie a hepatologie*, 2012, 66, s. 214–229.
- 5 Fried, M. W. – Shiffman, M. L. – Reddy, K. R. – Smith, C. – Marinus, G. – Goncales, F. L. – Haussinger, D. – Diago, M. – Carosi, G. – Dhumeaux, D. – Craxi, A. – Lin, A. – Hoffman, J. – Yu, J.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*, 2002, 347, s. 975–982.
- 6 Hadziyannis, S. J. – Sette, H. – Morgan, T. R. – Balan, V. – Diago, M. – Marcellin, P. – Ramadori, G. – Bodenheimer, H. – Bernstein, D. – Rizzetto, M. – Zeuzem, S. – Pockros, P. J. – Lin, A. – Ackrill, A. M.: Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C. *Ann Intern Med*, 2004, 140, s. 346–355.
- 7 Urbánek, P. – Subhanová, I. – Janoušová, E. – Dušek, L. – Mareček Z. – Brůha, R. – Petrtýl, J. – Brodanová, M.: Účinnost terapie pegylovaným interferonem a ribavirinem u pacientů s chronickou HCV infekcí. *Vnitř Léč*, 2009, 55, s. 474–479.
- 8 Urbánek, P. – Oltman, M. – Ivanovski, L. – Reháček, V. – Messinger, D. – Tietz, A. – Husa, P.: Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe. *European Journal of Gastroenterology and Hepatology*, 2011, 23, s. 1004–1010.

Crohnova nemoc a ulcerózní kolitida: klinický obraz, diagnostika a biologická léčba

prof. MUDr. Milan Lukáš, CSc. Klinické a výzkumné centrum pro střevní záněty ISCARE I.V.F., a. s.,
a Ústav klinické biochemie a laboratorní diagnostiky 1. LF UK, Praha

- 1 Lukáš, M. – Bortlík, M.: Etiologie a patogeneze ulcerózní kolitidy. Stále více otázek než jasných odpovědí. *Gastroent Hepatol*, 2011, 65, s. 56–64.
- 2 Bortlík, M. – Ďuricová, D. – Kouhout, P. M.: Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. *Gastroent Hepatol*, 2012, 66, s. 12–22.
- 3 Hoentjen, F. – Sakuraba, A. – Hanauer, S.: Update on the management of ulcerative colitis. *Curr Gastroenterol Rep*, doi: 10.1007.
- 4 Manza, M. – Michetti, P. – Seibold, F. – Rogler, G. – Beglinger, C.: Treatment algorithm for moderate to severe ulcerative colitis. Practical consensus recommendations, publikováno 27. 6. 2011, doi: 10.4414/smww.2011.13235.
- 5 Lichtiger, S. – Prezent, D. H. – Kornbluth, A., et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. *N Engl J Med*, 1994, 330, s. 1841–1845.
- 6 Van Assche, G. – D'Haens, G. – Noman, M., et al.: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. *Gastroenterology*, 2003, 125, s. 1025–1031.
- 7 Travis, S. P. L. – Stange, E. F. – Léman, M., et al.: European evidence-based consensus on the management of ulcerative colitis: Current management. *Journal of Crohn's and Colitis*, 2008, 2, s. 24–62.
- 8 Huang, X. – Lv, B. – Jin, H., et al.: A meta-analysis of the therapeutic effects of tumor necrosis factor- α blockers on ulcerative colitis. *Eur J Clin Pharmacol*, 2011, 67, s. 759–766.
- 9 Oussalah, A. – Evesque, L. – Laharie, D., et al.: A multicenter experience with infliximab for ulcerative colitis: Outcomes and predictors of response, optimization, colectomy, and hospitalization. *Am J Gastroenterol*, 2010, 105, s. 2617–2625.
- 10 Carter, C. T. – Leher, H. – Smith, P.: Impact of persistence with infliximab on hospitalizations in ulcerative colitis. *Am J Manag Care*, 2011, 17, s. 385–392.

Očkování v prevenci rakoviny děložního hrdla

MUDr. Lucie Mouková Masarykův onkologický ústav Brno, Oddělení gynekologické onkologie

- 1 Tachezy, R.: Epidemiologie genitální papillomavírové infekce ve světě a ČR, HPV a karcinom děložního čípku. *Moderní gynekologie a porodnictví*, 2006, 14, 4, dopl. A, s. 589–594.
- 2 Stern, P. L. – Kitchener, H. R.: *Vaccines for the Prevention of cervical Cancer*. Oxford Oncology Library, Oxford University Press, 2008.
- 3 Cibula, D. – Petruželka, L., et al.: *Onkogynekologie*. Grada, Praha, 2009.
- 4 Barr, E. – Sings, H. L.: Prophylactic HPV vaccines: New interventions for cancer control. *Vaccine*, 2008, 26, s. 1–14.
- 5 Kolombo, I. – Pors, J. – Porsova, M., et al.: Infekce lidským papillomavírem (human papillomavirus – HPV). *New EU Magazine of Medicine*, 2008, 2, s. 51–59.
- 6 Fait, T., et al.: *Očkování proti lidským papilomavírům*. Maxdorf, Praha, 2008.
- 7 Rotmensch, J. – Yamada, S. D.: Neoplasms of the Vulva and Vagina, in: Kufe, D. W. – Pollock, R. E. – Weichselbaum, R. R. – Bast, Jr. R. – Gansler, T. S. – Fea, H. J., edit.: *Holland-Frei Cancer Medicine*. B. C. Decker, Inc., Hamilton, Ontario, 2003.
- 8 Hercogová, J.: *Dermatologický pohled na infekce HPV (condylomata acuminata)*, *Farmakoterapie review: HPV infekce, její zdravotní důsledky, prevence*. Farmakon Press, 2007, s. 15–18.
- 9 ÚZIS ČR: *SVOD analýza*, www.svod.cz, verze 7.0 [2007].
- 10 Šlampa, P. – Tomášek J. – Korbička J. – Šeneklová Z.: Karcinom análního kanálu, in: Adam, Z. – Vorlíček, J. – Vaniček, J., et al.: *Diagnostické a léčebné postupy u maligních chorob*. Grada Publishing, Praha, 2004, s. 137–141.
- 11 Pacík, D. – Čermák A.: Maligní nádory penisu, in: Adam, Z. – Vorlíček, J. – Vaniček, J., et al.: *Diagnostické a léčebné postupy u maligních chorob*. Grada Publishing, Praha, 2004, s. 209–211.
- 12 www.vzp.cz, vyhledáno 13. 9. 2012.
- 13 www.ockovacentrum.cz, vyhledáno 13. 9. 2012.
- 14 www.zpma.cz/pojistenec/pro-klienty-zp-m-a/preventivni-prispevko-ve-programy/, vyhledáno 13. 9. 2012.
- 15 www.zpmvcr.cz/prevence/2012/program-ockovani-proti-hpv/, vyhledáno 13. 9. 2012.
- 16 www.ozp.cz/index.php?preventivni_ockovani_del_cipek, vyhledáno 13. 9. 2012.
- 17 www.rbp-zp.cz/pro-pojistence/bonusovy-program/zdravotni-programy/, vyhledáno 13. 9. 2012.
- 18 www.distribucevakcin.cz, vyhledáno 13. 9. 2012.